Business
Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY. Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be a
About this update from Vor Biopharma Inc.
[{"type":"image","alt":"Vor Biopharma","displaySize":"","headline":null,"caption":"Vor Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JC79HMZX268VMgkbnez1UQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec","width":300,"height":108},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/JC79HMZX268VMgkbnez1UQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MQ--/https://media.zenfs.com/en/globenewswire.com/06662e47289d17345678186e391880ec","width":300,"height":108}},"lazy":false},{"type":"text","content":"BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.","length":291,"tagName":"p"},{"type":"text","content":"Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET","length":61,"tagName":"p"},{"type":"text","content":"A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.","length":227,"tagName":"p"},{"type":"text","content":"About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.","length":381,"tagName":"p"},{"type":"text","content":"CONTACT: Media & Investor Contacts: Carl Mauch [email protected]","length":68,"tagName":"pre"},{"type":"text","content":"","length":0,"tagName":"p"}]